Detalhe da pesquisa
1.
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Ann Hematol
; 103(3): 759-769, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38273140
2.
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Am J Hematol
; 99(3): 350-359, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38165016
3.
Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission - a multi-center study.
Ann Hematol
; 102(6): 1383-1393, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37039874
4.
Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in AML patients.
J Cell Mol Med
; 26(21): 5486-5492, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36226545
5.
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
Br J Haematol
; 198(3): 535-544, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35438802
6.
Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients.
Hematol Oncol
; 40(5): 1097-1099, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468662
7.
Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
Clin Exp Rheumatol
; 40(7): 1336-1342, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35579092
8.
Posttransplant Cyclophosphamide and Antithymocyte Globulin versus Posttransplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis for Peripheral Blood Stem Cell Haploidentical Transplants: Comparison of T Cell and NK Effector Reconstitution.
J Immunol
; 205(5): 1441-1448, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32747504
9.
Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report.
Acta Haematol
; 145(5): 537-541, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35724631
10.
Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Haematologica
; 106(5): 1414-1422, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626866
11.
Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study.
Haematologica
; 106(3): 701-707, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32241844
12.
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Haematologica
; 106(12): 3100-3106, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34047178
13.
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trial.
Eur J Haematol
; 107(1): 111-121, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33765335
14.
Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide.
Acta Oncol
; 60(4): 466-474, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33112687
15.
Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.
J Immunol
; 202(7): 2141-2152, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30787107
16.
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life.
Ann Hematol
; 99(7): 1595-1604, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32417940
17.
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide.
Ann Hematol
; 99(6): 1341-1350, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32342134
18.
Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.
Biol Blood Marrow Transplant
; 25(7): 1465-1471, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30928627
19.
Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.
Biol Blood Marrow Transplant
; 25(5): 906-911, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30481598
20.
FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.
Cytokine
; 120: 85-87, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31035172